Teva Neuroscience, Inc. Release: COPAXONE(R) Significantly Reduced ...
KANSAS CITY, Mo.--(BUSINESS WIRE)--Final results from a five-year comparative imaging study examining the long-term effect of disease-modifying therapies (DMTs) in treatment-naive, early relapsing-remitting multiple sclerosis (RRMS) ...